CD40L/Mac-1 interaction inhibitors prevent the recruitment of inflammatory leukocytes and reduce inflammation in atherosclerosis by targeting CD11b, CD40LG, and integrin subunit beta 2 (ITGB2).625,627 The novel anti-CD45 ADC, initially used for anti-tumor therapy, is now being used to treat atherosclerosis by reducing the atherosclerotic plaque burden.628 Moreover, CAR-T cell therapy is currently under development. This evidence concerns the gene ITGB2 and atherosclerosis.